VOL. 1 OCTOBER. 2021

PEDIATRIC COVID-19 VACCINE

Official Newsletter of Doctors for You

COVID-19 during the first wave was easy on the pediatric population but with new variants and in subsequent waves it was found that mutations are equally morbid and can cause mortality like influenza, for which effective vaccines are available and are strongly recommended worldwide.

1: COMIRNATY AND PFIZER BIOTECH COVID-19
VACCINE

FDA approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of the third dose in certain immunocompromised individuals.

AGE INDICATION

12 YEARS OF AGE AND OLDER

DOSAGE

2-dose series separated by 21 days

Can be given to Moderately to severely immunocompromised people: With an additional dose at least 28 days after the initial 2-dose primary series.

OTHER GREAT READS INSIDE:

MODERNA COVID-19 VACCINE

ZYDUS CANDILA ZYCOVD NEEDLE FREE VACCINE

SPUTNIK -V

ASTRAZENECA VACCINE THE VACCINE HELPS PREVENT KIDS FROM GETTING COVID-19






2: MODERNA COVID-19 VACCINE







AGE INDICATION

18 Years of age and older

SCHEDULE

• 28 days apart 2 doses

A series started with COVID-19 vaccine (Moderna) should be completed with this product.

- Moderately to severely immunocompromised people:
- An additional dose can be considered at least 28 days after initial 2-dose primary series.

ADMINISTRATION

Intramuscular (IM) Injection in the deltoid muscle







Name of the Vaccine	Zydus Cadila commonly known as ZyCov-D
Manufactured by	Cadila Healthcare Limited
Trail Phase status	Three trial phases completed
Authorized by	DCGI (Drug Controller General of India)
Age Group	Above 12 years
Star point of the vaccine	Needless and DNA Plasma vaccine
Difference	Other vaccines are needle oriented

- 1. ORAL VACCINE
- 2. THREE DOSES

THE THREE DOSES ANY INDIVIDUAL WILL TAKE AS ON THE FIRST ZERO-DAY. AFTER THAT ON THE 28TH DAY AND THE LAST DOSE IS TO BE TAKEN ON THE 56TH DAY.





THE VACCINE HELPS PREVENT KIDS FROM GETTING COVID-19

CHILDREN CAN ALSO HAVE COMPLICATIONS SUCH AS MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN THAT MAY REQUIRE INTENSIVE CARE OR LONG-LASTING SYMPTOMS THAT AFFECT THEIR HEALTH AND WELL-BEING.

ALTHOUGH RARE, THE VIRUS CAN CAUSE DEATH COMPARED TO THE ADULT POPULATION THE VACCINE HELPS PREVENT OR REDUCE THE SPREAD OF COVID-19

GETTING VACCINATED FOR COVID-19 CAN HELP STOP OTHER VARIANTS FROM EMERGING

CASES OF COVID-19 ARE INCREASING AMONG CHILDREN, AND THE DELTA VARIANT APPEARS TO BE PLAYING A ROLE. REDUCING VIRAL TRANSMISSION BY GETTING VACCINATED ALSO REDUCES THE VIRUS' CHANCE TO MUTATE INTO NEW VARIANTS THAT MAY BE EVEN MORE DANGEROUS. HOWEVER, INCOMPLETE VACCINATION, MEANING NOT GETTING THE 2ND SHOT (FOR A VACCINE THAT REQUIRES 2 SHOTS), DOES GIVE VARIANTS A CHANCE TO EMERGE

POSSIBLE SIDE EFFECTS

YOUR CHILD MAY HAVE SOME SIDE EFFECTS, WHICH ARE NORMAL SIGNS THAT THEIR BODY IS BUILDING PROTECTION.

On the arm where you got the shot:



- Pain
- Redness
- Swelling

Throughout the rest of your body



- Tiredness
- Headache
- Muscle pain
- · Chills
- Fever
- Nausea



4: SPUTNIK -V

This is the first vaccination in India with a single dose. Thus, Sputnik-V will soon start their trials on children according to their age and weight.



5: ASTRAZENECA VACCINE

CLINICAL TRIAL FOR CHILDREN IS PAUSED.

HIGHLIGHTS OF MMR VACCINE AGAINST COVID -19

THE MMR VACCINE HAS BEEN HYPOTHESIZED TO PROTECT AGAINST SARS-COV-2 / COVID-19.

A MEASLES OUTBREAK IN 2018 MEANT THAT MANY HEALTH CARE WORKERS RECEIVED MMR.

A TEST-NEGATIVE CASE-CONTROL STUDY WAS PERFORMED ON 5905 HEALTH CARE WORKERS.

THE OR FOR TESTING POSITIVE IN RECENTLY VS NOT RECENTLY MMR-VACCINATED WAS 0.91.

THE OR IN MALES WAS 0.43, SUGGESTING A PROTECTIVE EFFECT IN MALES BUT NOT FEMALES.



CONCLUSION

Availability of an effective and safe pediatric COVID-19 vaccine appears mandatory for several clinical and epidemiological reasons. However, as the overcoming of all the problems that may delay the achievement of this goal is very difficult, strong The benefits of the vaccines far outweigh the risks. cooperation among governments, researchers, and pharmaceutical companies is highly desirable.

The vaccines are safe and highly effective. In clinical trials, there were no serious adverse events related to the vaccine, including myocarditis or anaphylaxis.

Clinical trials in children ages 5-11 years found the vaccine to be 90.7% effective in preventing symptomatic COVID-19. Safety data from the trials, which included more than 3,000 children who received the vaccine, found the most common reactions were pain at the injection site, fatigue and headache.



Clinical trial data have been analyzed and statistical modeling has been conducted to predict outcomes based on different scenarios. While benefits of vaccination are highly dependent on the incidence of COVID-19, overall analysis predicts that the number of clinically significant COVID-related outcomes prevented would clearly outweigh the numbers of vaccine-associated excess myocarditis cases.



OCTOBER 2021 VOL. 1

PEDIATRIC COVID-19 VACCINE

AROUND DFY

Monthly highlights

WE GOT DONOR SUPPORT FOR A MONTH TO UTTARAKHAND FLOODS RESPONSE (OCT 21)

Now we work on Uttarakhand & Kerala Flood area

- Dfy touched 5 million vaccination
- Gujrat cancer program launch
- Dfy own hospital VISTEX has got CT upgradation
- Plant inauguration at Mudigere (Kerala)-333LPM
- Rural program launch in Chandigarh and Haryana







Happy Diwali



Happy Diwali! With a gleam of auspicious Diyas and the holy chants, may happiness and prosperity fill your life forever!
Wishing You & Your Family a very Happy and Prosperous
Diwali! Troubles as light as Air, love as deep as Ocean, Friends as Solid as Diamonds, and Success as bright as Gold...

